Mdxhealth Adds Hereditary Prostate Cancer Genetic Test To Prostate Cancer Offering
Portfolio Pulse from Benzinga Newsdesk
MDxHealth SA (NASDAQ:MDXH) has introduced a non-invasive genetic test for hereditary prostate cancer, expanding its prostate cancer diagnostic offerings. The test, which uses a simple saliva sample, aims to provide insights into a patient's risk of developing prostate cancer, disease progression, and response to therapies. This addition is in line with National Comprehensive Cancer Network (NCCN) guidelines and is covered by Medicare and many commercial insurance plans. CEO Michael K. McGarrity believes this will contribute to the company's revenue and growth in the latter half of the year.
March 12, 2024 | 8:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MDxHealth SA introduces a new genetic test for hereditary prostate cancer, expected to enhance its diagnostic offerings and contribute to revenue growth.
The introduction of a new genetic test for hereditary prostate cancer by MDxHealth SA is directly aimed at expanding its diagnostic offerings in a market with a high demand for precision diagnostics. Given the test's alignment with NCCN guidelines and coverage by Medicare, it is likely to be well-received by both clinicians and patients, potentially leading to increased usage and, consequently, revenue growth for MDxHealth. The CEO's positive outlook on the impact of this addition to the company's portfolio further supports the expectation of a positive short-term impact on the stock.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100